Conference Coverage
Latest News
Jul 22, 2026 | Opinion
Improving CIS detection: Diagnostic tools and the urologist–pathologist relationship
FDA grants tentative approval to generic olaparib tablets across previously approved indications
Jul 22, 2026
Published data support PSMA-PET–guided selection for 177Lu-rosopatamab tetraxetan in mCRPC
Jul 22, 2026
Prof Declan Murphy on interpreting the PROTEUS trial in localized prostate cancer
Jul 22, 2026
Pearls & Perspectives: Understanding the Long-Term Health Effects of Military Exposures, With Shane Kronstedt, MD
Jul 22, 2026
Advertisement
Shorts
1:04
How the BRIDGE trial may impact bladder cancer treatment
23 minutes ago
by
Tyler Garman, MD
0:38
A new perioperative standard emerges for MIBC
a day ago
by
María Natalia Gandur Quiroga, MD, MSc
1:15
Matthew Galsky, MD, explains the significance of perioperative EV/pembro in MIBC
2 days ago
by
Matthew Galsky, MD
0:42
From symptoms to systems: How functional urology evolved
5 days ago
by
Sasha Vereecken, RN
1:22
First Assist: The evolving role of cystectomy in bladder cancer
6 days ago
by
Taylor Goodstein, MD(+1 more)
0:42
Closing the gap: Urologists and female sexual health
7 days ago
by
Melissa Moran, DO
0:54
Testosterone and prostate cancer risk: A balanced message
8 days ago
by
Helen L. Bernie, DO, MPH
1:03
Beyond cisplatin eligibility: A new MIBC standard
9 days ago
by
María Natalia Gandur Quiroga, MD, MSc
0:39
Anatomy vs function: What reconstruction really means
12 days ago
by
Sasha Vereecken, RN
1:40
The role of focal therapy in an evolving prostate cancer landscape
13 days ago
by
Joy Maulik, CRNP(+1 more)
From GSM guidance to HRT reform: A landmark year for women’s health
2025 featured multiple advancements in women's health aimed at enhancing treatment options and awareness.
Inguinal lymph node dissection in penile cancer
"Deep ILND is indicated for clinically positive lymph nodes and/or positive lymph nodes on frozen pathological analysis of the superficial nodal packet," write Bahrom J. Ostad, MD, and Stephen H. Culp, MD, PhD, FACS.
Inside HoLEP: Irina Jaeger, MD, discusses patient selection and technique
Jaeger emphasizes that the ideal HoLEP candidate is any patient with bothersome lower urinary tract symptoms due to BPH, including those with urinary retention or intolerance to medication.
Podcasts
Videos
Urology Times Digital Edition
"Deep ILND is indicated for clinically positive lymph nodes and/or positive lymph nodes on frozen pathological analysis of the superficial nodal packet," write Bahrom J. Ostad, MD, and Stephen H. Culp, MD, PhD, FACS.
"The overall 0% impact to urology does not help urology practices deal with increasing costs incurred for staff, rent, supplies, and other overhead," write Jonathan Rubenstein, MD, and Mark Painter.
"If 2025 showed us anything, it is the power of combining scientific progress with public engagement," writes Michael S. Cookson, MD, MMHC, FACS.
"Once money is in a Roth IRA, the withdrawal rules depend on whether the funds are contributions, conversions, or earnings," writes Julie Khazan, CFP.
The approval is supported by results from the phase 3 KEYNOTE-905/EV-303 trial.
The ExactVu micro-ultrasound platform demonstrated noninferior detection of clinically significant prostate cancer vs MRI.
"The OBBA includes broad and sweeping changes that will have a profound impact," writes Allan Shen, CFP.
The ENDURE 1 study plans to enroll up to 60 patients with benign ureteric strictures.
The phase 3 PSMAddition trial assessed the combination of 177Lu-PSMA-617 plus ADT/ARPI in an earlier stage of metastatic prostate cancer.
Jaeger emphasized that the ideal HoLEP candidate is any patient with bothersome lower urinary tract symptoms due to BPH, including those with urinary retention or intolerance to medication
Continuing Medical Education
Advertisement
All News
Advertisement
Experts discuss why CIS is frequently underrecognized, highlighting the subtle clinical and cystoscopic features of the disease and the importance of integrating multiple factors to improve detection.
This marks the first phase 3 study of a targeted radiopharmaceutical therapy in clear cell renal cell carcinoma.
Tyler S. Garman, MD, highlights phase 2 data on intravesical gemcitabine and docetaxel as first-line treatment of BCG‒naïve NMIBC.
Results from a first-in-human phase 0 feasibility trial showed that combined bladder and kidney transplantation was technically feasible.
Kathryn H. Gessner, MD, PhD, discusses the current limitations in identifying appropriate candidates for bladder-preserving trimodal therapy, the promise of utDNA, and why shared decision-making remains essential.
A secondary analysis of the ASPIRE trial found residual stone volume—not conventional stone-free status, baseline volume, or density—is the strongest predictor of post-ureteroscopy health care utilization, with each 100-mm³ increase doubling event odds.
Department of Defense announces annual testosterone deficiency screening for service members
Published: | Updated:
The Department of Defense will begin annual testosterone deficiency screening for service members aged 30 years and older.
Richard N. Schlussel, MD, discusses how advances in robotic surgery and artificial intelligence are expected to transform care in pediatric urology.
Jamie Michael, MD, highlights a study exploring the impact of MRI and genomics on "extreme" grade reclassification in men on active surveillance.
Dose interruption rather than discontinuation addresses most gemcitabine intravesical system (Inlexzo) adverse events, with designated champions supporting consistent patient management, according to Elizabeth Mobley, MD.
Advertisement
Elizabeth Mobley, MD, shares practical tips for counseling patients and managing adverse events during treatment with the gemcitabine intravesical system.
Proactive adverse event counseling and a specific hydration protocol are the primary tools for supporting patient retention through the gemcitabine intravesical system's (Inlexzo) extended treatment course, according to Mobley.
The phase 2 study is assessing whether an adaptive treatment approach can improve responses and enable treatment pauses for select patients.
University of Florida chief residents share practical advice for trainees on building mentorship networks, maintaining well-being, and navigating the personal and professional challenges of urology residency.
The pivotal phase 3 Himalayas-1 trial will evaluate rinzimetostat plus darolutamide vs with physician's choice of an ARPI or docetaxel.
Advertisement
Advertisement
Trending on Urology Times
1
Experts discuss the challenge of detecting CIS in bladder cancer
2
Phase 3 trial launches of CAIX-targeted radiopharmaceutical for ccRCC
3
Study shows durable 3-year outcomes with first-line gemcitabine/docetaxel in NMIBC
4
FDA grants tentative approval to generic olaparib tablets across previously approved indications
5